UAE Drug Registration: The Complete 2026 Guide to MOHAP & EDE

UAE Drug Registration: The Complete 2026 Guide to MOHAP & the Emirates Drug Establishment (EDE)

Answer in brief: Pharmaceutical product registration in the United Arab Emirates is now centralized at the federal level under the Emirates Drug Establishment (EDE) — established by Federal Decree-Law No. 38 of 2024 — which has taken over the drug regulatory functions previously handled by the Ministry of Health and Prevention (MOHAP). To register a pharmaceutical product, biologic, or medical device in the UAE, a foreign manufacturer typically needs (1) a locally licensed agent or distributor authorized to act in front of the EDE, (2) a complete CTD/eCTD dossier with bilingual Arabic-English labelling that meets EDE specifications, (3) a valid GMP certificate from a recognized authority, and (4) successful technical and pricing review. Standard timelines run 9–18 months for new generics; the verification pathway (for products already approved by reference authorities such as the EMA, FDA, MHRA, or PMDA) is shorter.

Reviewed by Dr. Rasha Ringa, Founder & General Manager, PKCS. Last reviewed: April 2026.

What is the UAE pharmaceutical regulatory framework after Federal Decree-Law 38 of 2024?

The UAE pharmaceutical regulatory landscape changed materially with the issuance of Federal Decree-Law No. 38 of 2024, which established the Emirates Drug Establishment as a federal authority responsible for the regulation of pharmaceutical products, biologics, complementary medicines, advanced therapies, and certain classes of medical devices across all seven emirates. Before this law, pharmaceutical product registration was handled by MOHAP’s drug registration department under the broader umbrella of the Ministry of Health and Prevention. The 2024 reform consolidates drug regulatory authority into a dedicated, specialist body — modelled on similar federal authorities in mature regulatory jurisdictions.

For practical purposes, manufacturers should now think of the UAE pharmaceutical regulatory framework in three layers:

  • EDE — the central drug regulatory authority. Handles dossier review, marketing authorization, lifecycle management, GMP certification recognition, and pharmacovigilance for products under its scope.
  • MOHAP — continues to regulate healthcare facilities, hospital licensing, healthcare professional registration, and certain public health programs. MOHAP and EDE coordinate where their domains overlap (e.g., post-marketing surveillance reaching healthcare facilities).
  • Local emirate health authorities — the Department of Health Abu Dhabi (DoH), the Dubai Health Authority (DHA), and counterparts in other emirates retain regulatory roles over healthcare facilities and certain emirate-specific licensing within their jurisdictions, though pharmaceutical product registration is federal.

Who registers what under the EDE?

EDE’s scope covers a wider range of regulated products than the legacy MOHAP system explicitly. Manufacturers should map their products to the correct EDE regulatory pathway at the strategy stage:

  • Pharmaceutical products — chemical entities, generics, combination products. Both prescription (Rx) and over-the-counter (OTC).
  • Biologics and biosimilars — recombinant proteins, monoclonal antibodies, vaccines, blood-derived products, biosimilars referencing innovator biologics.
  • Advanced therapies — gene therapies, cell therapies, and tissue-engineered products.
  • Medical devices — under GHTF-style risk classification (Class I, IIa, IIb, III); device registration in the UAE has its own track that operates in parallel with pharmaceutical registration.
  • Complementary medicines and herbal products — registered under a separate complementary medicines pathway.
  • Veterinary medicinal products — handled under a separate framework where applicable.

What is the step-by-step UAE drug registration process?

The standard EDE pharmaceutical registration process follows seven phases. Timelines below assume a complete, high-quality dossier for a new generic product without major deficiencies.

  1. Pre-registration strategy and local agent appointment. A foreign manufacturer must appoint a locally licensed entity authorized to act on its behalf in front of the EDE. The local agent receives correspondence, holds the marketing authorization (where regulations require local MA holding), submits dossiers, and represents the manufacturer in regulatory interactions. PKCS provides this local representative service.
  2. Dossier gap assessment. A regulatory affairs team reviews the existing global dossier against EDE country-specific requirements. Common gaps for foreign manufacturers include EDE-specific Module 1 administrative documents, Arabic translation of patient information leaflets and packaging artwork, ICH Climate Zone IVb stability data (UAE conditions), and regional pharmacopoeial references where required.
  3. Dossier compilation and submission. The technical dossier is assembled in CTD/eCTD format. EDE accepts the standard ICH CTD with country-specific Module 1 overlays (cover letter, fees, local agent power of attorney, GMP certificate, Certificate of Pharmaceutical Product in WHO format, sample artwork). Submission is made through the EDE electronic portal.
  4. Administrative review. EDE’s administrative team verifies completeness against the formal checklist before the dossier moves to technical review. Incomplete dossiers are returned for resubmission, costing weeks. This is the most common cause of avoidable delay.
  5. Technical review. Therapeutic area committees review quality (Module 3), nonclinical (Module 4), and clinical (Module 5) data. Reviewers issue deficiency letters listing questions and requests for additional information. Most products go through one to three deficiency cycles before approval.
  6. Pricing review. The proposed UAE retail price is reviewed against international reference pricing — EDE compares prices in country of origin, neighbouring markets, and reference jurisdictions. Pricing approval is its own short cycle.
  7. Marketing authorization issuance. The MA certificate is issued, valid for five years, after which renewal is required. The product enters the EDE registered products database and is eligible for commercialization through the local agent’s distribution channels.

End-to-end timeline for a new generic with a complete, high-quality dossier: 9–18 months. Innovator products with novel dossiers can run 18–30 months. Products with reference approval from EMA, FDA, MHRA, PMDA, or Health Canada often qualify for the verification pathway and shorter review.

What are the EDE verification and accelerated pathways?

EDE — like its predecessor MOHAP — operates a verification pathway for products that already hold marketing authorization in recognized reference jurisdictions. Where the dossier and approval status from the reference market are accepted, EDE conducts a streamlined review focused on country-specific elements (labelling, pricing, local agent designation, Arabic translation) rather than a full re-evaluation of the global quality, safety, and efficacy package.

The verification pathway materially compresses time-to-MA — often by 30–50% — for innovator products approved by:

  • European Medicines Agency (EMA) — centralized procedure approvals
  • US Food and Drug Administration (FDA)
  • UK Medicines and Healthcare products Regulatory Agency (MHRA)
  • Japanese Pharmaceuticals and Medical Devices Agency (PMDA)
  • Health Canada
  • Therapeutic Goods Administration (TGA) Australia
  • Swissmedic

For generics, a similar streamlined pathway exists where the reference product is approved in a recognized authority and bioequivalence data is from a PIC/S-accredited bioanalytical site. EDE additionally operates an accelerated review track for products addressing unmet medical needs and public health priorities — manufacturers can apply for accelerated review at the pre-submission strategy stage.

What documentation does the UAE EDE dossier require?

EDE dossier requirements broadly follow the ICH-CTD structure. Module 2–5 scientific content is largely interchangeable with EU and US submissions for products built to those standards. Module 1 is country-specific and is the most common source of administrative deficiencies.

Module 1 — Administrative and country-specific (EDE overlay)

  • Cover letter
  • EDE application form
  • Power of attorney from manufacturer to local agent (notarized and legalized through the UAE consulate in the country of origin)
  • Certificate of Pharmaceutical Product (CPP) in WHO format from the country of origin or reference market
  • Manufacturing licence of the producer
  • GMP certificate from a recognized authority (PIC/S inspectorate, EMA, FDA, MHRA, etc.)
  • Marketing authorization in country of origin or reference market
  • Pricing dossier — ex-factory price, CIF price, proposed UAE retail price, and benchmark prices in reference markets
  • Bilingual artwork — primary packaging, secondary packaging, patient information leaflet (PIL), and summary of product characteristics (SmPC) in both Arabic and English
  • Reference samples for laboratory analysis where required
  • Fee receipts

Module 2 — Common Technical Document summaries

Quality Overall Summary (QOS), Nonclinical Overview and Summary, Clinical Overview and Summary. These are essentially identical to EU and US CTD modules.

Module 3 — Quality (CMC)

Drug substance and drug product chemistry, manufacturing, and controls. UAE EDE expects ICH Climate Zone IVb stability data (30°C/75%RH) appropriate for the Gulf region’s hot and humid conditions. Manufacturers using only Zone II stability data should plan to add Zone IVb studies for UAE submission.

Module 4 — Nonclinical study reports

For generics with established active pharmaceutical ingredients, Module 4 is typically referenced rather than fully reproduced. For new chemical entities and biologics, full nonclinical data is required.

Module 5 — Clinical study reports

For generics, primarily bioequivalence study reports against an acceptable reference product. For new chemical entities, full clinical development data including pivotal trials. Biosimilars follow a separate, more demanding pathway with comparability data, immunogenicity assessment, and clinical similarity studies.

What are the UAE Arabic labelling and bilingual requirements?

UAE pharmaceutical products must carry labels, patient information leaflets, and packaging artwork in both Arabic and English. The Arabic translation must be a faithful, regulatory-grade rendering of the English source — translation errors and inconsistencies between the SmPC and PIL are a frequent cause of artwork rejection.

Other UAE labelling expectations include: country-of-origin declaration, batch number and expiry date in standardized format, prescription status indicator, GS1 barcode (increasingly required), Arabic generic name in addition to brand name, and storage conditions consistent with Zone IVb stability data. PKCS produces Arabic regulatory documentation in-house to avoid the typical errors of commercial translation services unfamiliar with pharmacovigilance and regulatory science terminology.

What are the most common rejection reasons in UAE EDE submissions?

The high-frequency reasons EDE returns dossiers or issues major deficiencies fall into four categories:

Administrative completeness failures

Missing or incorrectly legalized power of attorney from the manufacturer to the local agent; CPP not in WHO format or from a non-recognized country; expired GMP certificate; incomplete Module 1; mismatched details between the application form and the dossier.

Bilingual artwork issues

Arabic translation errors; inconsistencies between the SmPC, PIL, and packaging artwork; missing GS1 barcode positioning; incorrect prescription status indicator; brand name conflicts with already-registered UAE products.

Stability data gaps

Stability data presented only at ICH Zone II conditions without Zone IVb data appropriate for UAE storage conditions. EDE expects full Zone IVb (30°C/75%RH) shelf-life data.

Bioequivalence study deficiencies (generics)

Reference product not approved in a recognized market; bioequivalence study conducted at a non-PIC/S-accredited bioanalytical site; inadequate statistical analysis or fasted-vs-fed justification; insufficient subject numbers for the variability of the active substance.

Variations, renewals, and post-approval lifecycle

An EDE marketing authorization is valid for five years and must be renewed before expiry. Renewals confirm continued GMP, pharmacovigilance compliance, and a favourable benefit-risk profile. Variations during the five-year cycle follow categories broadly aligned with EU variation classifications. Common variations for foreign manufacturers include manufacturing site changes, excipient changes, packaging changes, and indication extensions. PKCS coordinates variations to minimize the regulatory load on the manufacturer.

Pharmacovigilance during the post-approval phase is a mandatory ongoing obligation. The marketing authorization holder must report serious adverse drug reactions occurring in the UAE to the EDE pharmacovigilance unit within the regulatory deadlines, submit periodic safety update reports (PSURs), and participate in any post-marketing safety initiatives EDE requires. PKCS pharmacovigilance services include the qualified person for pharmacovigilance (QPPV) function for the UAE and full PV system implementation.

How does UAE registration interact with the GCC central pathway?

The UAE participates in the GCC central drug registration pathway operated under the GCC Health Council. A product approved through the GCC central registration is recognized for placement on the market in all six GCC member states (Saudi Arabia, the UAE, Kuwait, Qatar, Bahrain, Oman) — though each country retains national authority over pricing and certain post-approval matters. For manufacturers planning a multi-country GCC entry, a strategic decision at the start of the regulatory programme is whether to file nationally in each country, file via the GCC central pathway, or pursue a hybrid approach. PKCS advises clients on this trade-off as part of regulatory consultation engagements.

How does PKCS support UAE drug registration?

PKCS is a Dubai-registered regulatory consulting firm with deep specialization in UAE EDE/MOHAP regulatory affairs. Founder Dr. Rasha Ringa leads engagements ranging from one-time registration projects to long-term lifecycle management for portfolios of products. Typical PKCS engagements for UAE drug registration include:

  • Regulatory affairs — full dossier preparation and submission to EDE, deficiency response management, and marketing authorization through to issuance.
  • Local representative services — PKCS as the registered local agent of record for foreign manufacturers without a UAE presence.
  • Pharmacovigilance — UAE-specific PV system implementation and QPPV provision.
  • GMP support — preparation of foreign manufacturing sites for EDE-coordinated GMP inspection.
  • Bilingual Arabic-English regulatory documentation.
  • Cross-market strategy — coordinating UAE registration with Iraq, Saudi Arabia (SFDA), and the GCC central pathway.

Most engagements start with a regulatory strategy gap assessment that maps the manufacturer’s existing dossier against EDE requirements and gives a realistic, country-specific timeline.

Frequently asked questions

What is the difference between MOHAP and the Emirates Drug Establishment (EDE)?

Federal Decree-Law No. 38 of 2024 established the Emirates Drug Establishment as a dedicated federal authority responsible for the regulation of pharmaceuticals, biologics, advanced therapies, and certain medical devices. EDE took over the drug regulatory functions previously housed within MOHAP. MOHAP retains its broader role over healthcare facility licensing, professional registration, and public health. For pharmaceutical product registration, EDE is now the relevant authority.

How long does drug registration in the UAE take?

For a new generic with a complete, high-quality dossier, 9–18 months from first submission to marketing authorization is realistic. Innovator products with novel dossiers can take 18–30 months. The verification pathway for products with reference approvals from EMA, FDA, MHRA, PMDA, Health Canada, TGA, or Swissmedic is materially shorter.

Does a foreign manufacturer need a local UAE entity to register a drug?

No. Foreign manufacturers do not need their own UAE entity. They do need a locally licensed agent — typically a pharmaceutical consulting firm or local distributor — authorized to act on their behalf. PKCS provides this local representative service in the UAE under local representative services.

What stability data does the UAE EDE require?

EDE expects ICH Climate Zone IVb stability data (30°C/75%RH) appropriate for UAE conditions. Manufacturers with Zone II data only should plan to add Zone IVb studies before submission.

Does the UAE accept bioequivalence studies from any site?

EDE expects bioequivalence studies to come from PIC/S-accredited or equivalent bioanalytical sites. Studies from non-recognized sites are commonly cited as deficiencies and may require repetition.

Is the marketing authorization permanent or does it require renewal?

UAE marketing authorization is valid for five years and must be renewed before expiry. Renewal requires confirmation of continued GMP, pharmacovigilance compliance, and a favourable benefit-risk profile.

What pharmacovigilance obligations apply after UAE registration?

The marketing authorization holder must maintain a pharmacovigilance system, report serious adverse drug reactions in the UAE within the regulatory deadlines, submit periodic safety reports, and operate under a named QPPV. PKCS provides full pharmacovigilance services for the UAE.

Can I register a product in the UAE if it is not approved in any reference market?

Yes, but the technical review will be more intensive and longer. Most foreign manufacturers register products that already have a reference approval; the verification pathway substantially shortens review time when this is available.

How does UAE registration interact with Iraq and Saudi Arabia registration?

Iraq, the UAE, and Saudi Arabia each have separate national pathways. The GCC central drug registration covers Saudi Arabia, UAE, and four other GCC states but not Iraq (Iraq is not a GCC member). PKCS advises clients on the optimal multi-market sequencing — see our Iraq drug registration pillar guide and regulatory consultation services.

How do I respond to a deficiency letter from EDE?

Address every deficiency point in writing with supporting evidence and references to the source dossier sections. Most products require one to three deficiency response cycles before approval; PKCS manages these cycles for clients to maintain dossier integrity.

Talk to PKCS about UAE drug registration

PKCS works with pharmaceutical, biotechnology, and medical device companies registering products in the UAE for the first time, expanding existing portfolios, navigating MOHAP-to-EDE transitions for legacy products, or managing post-approval lifecycle. Get in touch for a confidential discussion of your UAE regulatory strategy.

Related resources